FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328049154> ?p ?o ?g. }

• W4328049154 endingPage "1066" @default.
• W4328049154 startingPage "1066" @default.
• W4328049154 abstract "Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making. Objective To evaluate HTE of therapeutic-dose heparin for patients hospitalized for COVID-19 and to compare approaches to assessing HTE. Design, Setting, and Participants Exploratory analysis of a multiplatform adaptive RCT of therapeutic-dose heparin vs usual care pharmacologic thromboprophylaxis in 3320 patients hospitalized for COVID-19 enrolled in North America, South America, Europe, Asia, and Australia between April 2020 and January 2021. Heterogeneity of treatment effect was assessed 3 ways: using (1) conventional subgroup analyses of baseline characteristics, (2) a multivariable outcome prediction model (risk-based approach), and (3) a multivariable causal forest model (effect-based approach). Analyses primarily used bayesian statistics, consistent with the original trial. Exposures Participants were randomized to therapeutic-dose heparin or usual care pharmacologic thromboprophylaxis. Main Outcomes and Measures Organ support–free days, assigning a value of −1 to those who died in the hospital and the number of days free of cardiovascular or respiratory organ support up to day 21 for those who survived to hospital discharge; and hospital survival. Results Baseline demographic characteristics were similar between patients randomized to therapeutic-dose heparin or usual care (median age, 60 years; 38% female; 32% known non-White race; 45% Hispanic). In the overall multiplatform RCT population, therapeutic-dose heparin was not associated with an increase in organ support–free days (median value for the posterior distribution of the OR, 1.05; 95% credible interval, 0.91-1.22). In conventional subgroup analyses, the effect of therapeutic-dose heparin on organ support–free days differed between patients requiring organ support at baseline or not (median OR, 0.85 vs 1.30; posterior probability of difference in OR, 99.8%), between females and males (median OR, 0.87 vs 1.16; posterior probability of difference in OR, 96.4%), and between patients with lower body mass index (BMI &amp;lt;30) vs higher BMI groups (BMI ≥30; posterior probability of difference in ORs &amp;gt;90% for all comparisons). In risk-based analysis, patients at lowest risk of poor outcome had the highest propensity for benefit from heparin (lowest risk decile: posterior probability of OR &amp;gt;1, 92%) while those at highest risk were most likely to be harmed (highest risk decile: posterior probability of OR &amp;lt;1, 87%). In effect-based analysis, a subset of patients identified at high risk of harm ( P = .05 for difference in treatment effect) tended to have high BMI and were more likely to require organ support at baseline. Conclusions and Relevance Among patients hospitalized for COVID-19, the effect of therapeutic-dose heparin was heterogeneous. In all 3 approaches to assessing HTE, heparin was more likely to be beneficial in those who were less severely ill at presentation or had lower BMI and more likely to be harmful in sicker patients and those with higher BMI. The findings illustrate the importance of considering HTE in the design and analysis of RCTs. Trial Registration ClinicalTrials.gov Identifiers: NCT02735707 , NCT04505774 , NCT04359277 , NCT04372589" @default.
• W4328049154 created "2023-03-22" @default.
• W4328049154 creator A5000380712 @default.
• W4328049154 creator A5000735539 @default.
• W4328049154 creator A5000792294 @default.
• W4328049154 creator A5001670387 @default.
• W4328049154 creator A5002194816 @default.
• W4328049154 creator A5002226085 @default.
• W4328049154 creator A5003737951 @default.
• W4328049154 creator A5004322015 @default.
• W4328049154 creator A5004629712 @default.
• W4328049154 creator A5004675595 @default.
• W4328049154 creator A5004937694 @default.
• W4328049154 creator A5006702259 @default.
• W4328049154 creator A5007218791 @default.
• W4328049154 creator A5007893863 @default.
• W4328049154 creator A5008136895 @default.
• W4328049154 creator A5008504819 @default.
• W4328049154 creator A5010475608 @default.
• W4328049154 creator A5011166514 @default.
• W4328049154 creator A5012050391 @default.
• W4328049154 creator A5012706547 @default.
• W4328049154 creator A5013254241 @default.
• W4328049154 creator A5013704262 @default.
• W4328049154 creator A5013873904 @default.
• W4328049154 creator A5014347191 @default.
• W4328049154 creator A5014471456 @default.
• W4328049154 creator A5014914458 @default.
• W4328049154 creator A5015444962 @default.
• W4328049154 creator A5016702023 @default.
• W4328049154 creator A5017038212 @default.
• W4328049154 creator A5018342534 @default.
• W4328049154 creator A5018947556 @default.
• W4328049154 creator A5019191423 @default.
• W4328049154 creator A5019303744 @default.
• W4328049154 creator A5019380741 @default.
• W4328049154 creator A5020471552 @default.
• W4328049154 creator A5020634713 @default.
• W4328049154 creator A5020839633 @default.
• W4328049154 creator A5020963388 @default.
• W4328049154 creator A5021200051 @default.
• W4328049154 creator A5021692759 @default.
• W4328049154 creator A5021959578 @default.
• W4328049154 creator A5022128182 @default.
• W4328049154 creator A5022288083 @default.
• W4328049154 creator A5023476325 @default.
• W4328049154 creator A5023858070 @default.
• W4328049154 creator A5024626733 @default.
• W4328049154 creator A5024931198 @default.
• W4328049154 creator A5025028312 @default.
• W4328049154 creator A5025632184 @default.
• W4328049154 creator A5026398037 @default.
• W4328049154 creator A5026621846 @default.
• W4328049154 creator A5028060173 @default.
• W4328049154 creator A5028084943 @default.
• W4328049154 creator A5029058133 @default.
• W4328049154 creator A5029744589 @default.
• W4328049154 creator A5030570000 @default.
• W4328049154 creator A5031956134 @default.
• W4328049154 creator A5032367961 @default.
• W4328049154 creator A5032411762 @default.
• W4328049154 creator A5033174484 @default.
• W4328049154 creator A5034441524 @default.
• W4328049154 creator A5034628501 @default.
• W4328049154 creator A5034728785 @default.
• W4328049154 creator A5034765888 @default.
• W4328049154 creator A5036112408 @default.
• W4328049154 creator A5036872856 @default.
• W4328049154 creator A5037880923 @default.
• W4328049154 creator A5037956429 @default.
• W4328049154 creator A5038646603 @default.
• W4328049154 creator A5039149214 @default.
• W4328049154 creator A5039321004 @default.
• W4328049154 creator A5039321983 @default.
• W4328049154 creator A5039409201 @default.
• W4328049154 creator A5039640379 @default.
• W4328049154 creator A5040469659 @default.
• W4328049154 creator A5040595008 @default.
• W4328049154 creator A5040791207 @default.
• W4328049154 creator A5040889843 @default.
• W4328049154 creator A5041492796 @default.
• W4328049154 creator A5041519561 @default.
• W4328049154 creator A5042383153 @default.
• W4328049154 creator A5043424881 @default.
• W4328049154 creator A5043765709 @default.
• W4328049154 creator A5044263870 @default.
• W4328049154 creator A5044432917 @default.
• W4328049154 creator A5044476789 @default.
• W4328049154 creator A5044527590 @default.
• W4328049154 creator A5044700114 @default.
• W4328049154 creator A5044905628 @default.
• W4328049154 creator A5045012686 @default.
• W4328049154 creator A5045986606 @default.
• W4328049154 creator A5046167047 @default.
• W4328049154 creator A5046325783 @default.
• W4328049154 creator A5046329721 @default.
• W4328049154 creator A5047750906 @default.
• W4328049154 creator A5048546714 @default.

• next